Condition: Non Small Cell Lung Cancer · Small Cell Lung Cancer · Sponsor: Shanghai Henlius Biotech
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.
This description comes directly from the study's public registry record.
Yongqing Lin · 18925185148 · yongqing_lin@henlius.com
Always discuss trial participation with your own doctor first.
| The Second Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Fujian Cancer Hospital | Fu'zhou, Fujian, China | Recruiting |
| Cancer Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
| The People's Hospital of Guangxi Zhuangzu Autonomous Region | Nanning, Guangxi, China | Recruiting |
| Cangzhou People's Hospital | Cangzhou, Hebei, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| The First Affiliated Hospital of Xinxiang Medical University | Xinxiang, Henan, China | Recruiting |
| Hubei Cancer Hospital | Wuha, Hubei, China | Recruiting |
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| THE Affiliated Hospital of Xuzhou Medical University | Xuzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07253142